UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/18.12.24 | Market Closed - BOERSE MUENCHEN 16:40:25 19/06/2024 BST | ||
| 1.3 EUR | 0.00% |
|
| Current month | +17.12% | ||
| 1 month | +41.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 1.3 | 0.00% |
| 18/06/24 | 1.3 | -10.96% |
| 17/06/24 | 1.46 | -11.52% |
| 14/06/24 | 1.65 | +5.10% |
| 13/06/24 | 1.57 | +3.97% |
Real-time BOERSE MUENCHEN
Last update June 19, 2024 at 04:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC6HHS |
| ISIN | DE000HC6HHS7 |
| Date issued | 05/05/2023 |
| Strike | 550 $ |
| Maturity | 18/12/2024 (182 Days) |
| Parity | 10 : 1 |
| Emission price | 1.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.54 € |
|---|---|
| Lowest since issue | 0.45 € |
| Spread | 0.14 € |
| Spread % | 10.61% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
467.3
USD
Average target price
463.4
USD
Spread / Average Target
-0.83%
- Stock Market
- Warrants
- Warrant
